

# A *Drosophila* model for LRRK2-linked parkinsonism

Zhaohui Liu\*<sup>†</sup>, Xiaoyue Wang<sup>‡</sup>, Yi Yu\*<sup>†</sup>, Xueping Li\*<sup>†</sup>, Tao Wang<sup>‡</sup>, Haibing Jiang\*<sup>†</sup>, Qiuting Ren<sup>‡</sup>, Yuchen Jiao<sup>‡</sup>, Akira Sawa\*<sup>§</sup>, Timothy Moran\*, Christopher A. Ross\*<sup>†§¶</sup>, Craig Montell<sup>§</sup>, and Wanli W. Smith\*<sup>†¶</sup>

\*Department of Psychiatry, <sup>†</sup>Division of Neurobiology, and Departments of <sup>§</sup>Neuroscience and <sup>¶</sup>Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287; and <sup>‡</sup>Department of Biological Chemistry, Center for Sensory Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205

Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved December 12, 2007 (received for review September 6, 2007)

Mutations in the leucine-rich repeat kinase (*LRRK2*) gene cause late-onset autosomal dominant Parkinson's disease (PD) with pleiomorphic pathology. Previously, we and others found that expression of mutant *LRRK2* causes neuronal degeneration in cell culture. Here we used the *GAL4/UAS* system to generate transgenic *Drosophila* expressing either wild-type human *LRRK2* or *LRRK2*-G2019S, the most common mutation associated with PD. Expression of either wild-type human *LRRK2* or *LRRK2*-G2019S in the photoreceptor cells caused retinal degeneration. Expression of *LRRK2* or *LRRK2*-G2019S in neurons produced adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early mortality. Expression of mutant G2019S-*LRRK2* caused a more severe parkinsonism-like phenotype than expression of equivalent levels of wild-type *LRRK2*. Treatment with L-DOPA improved mutant *LRRK2*-induced locomotor impairment but did not prevent the loss of tyrosine hydroxylase-positive neurons. To our knowledge, this is the first *in vivo* "gain-of-function" model which recapitulates several key features of *LRRK2*-linked human parkinsonism. These flies may provide a useful model for studying *LRRK2*-linked pathogenesis and for future therapeutic screens for PD intervention.

dopaminergic neuron | Parkinson's disease

Mutations in the leucine-rich repeat kinase (*LRRK2*) gene cause late-onset autosomal dominant Parkinson's disease (PD) with pleiomorphic pathology, including nigral degeneration, Lewy bodies, and neurofibrillary tau-positive tangles (1–4). The *LRRK2* gene spans a 144-kb genomic region, with 51 exons encoding 2,527 aa. The gene is expressed in all tissues examined, although at low levels. *LRRK2* contains multiple conserved domains including MAP kinase kinase kinase (MAPKKK), leucine-rich repeat (LRR), GTPase (ROC and COR), and WD40 domain (1, 2). The normal biological function of *LRRK2* is unclear, although suppression of *LRRK2* with siRNAs or a dominant inhibitory allele leads to increased neurite length and complexity (5). The discovery of PD-linked point mutations in almost all of the predicted domains of *LRRK2*, the absence of deletions or truncations, and the dominant inheritance of the disease suggest a "gain-of-function" mechanism for *LRRK2*-linked PD.

The *LRRK2* MAPKKK domain contains sequence homology to both serine/threonine and tyrosine kinases. Several pathogenic mutations of *LRRK2* in PD have been found within the protein kinase domain active segment (e.g., G2019S), suggesting that these mutations may cause pathology through altering the enzymatic activity of *LRRK2* (1, 2, 6). G2019S is the most common mutation in *LRRK2*-associated PD (7–9) and is believed to increase *LRRK2* kinase activity in assays to measure autophosphorylation or phosphorylation of generic substrates (5, 10–14). Controversy exists regarding whether the other PD mutations alter *LRRK2* kinase activity (14, 15). Abolishing *LRRK2* kinase activity diminishes the toxicity of all PD mutants tested in cell culture (11, 12), suggesting that *LRRK2* protein kinase activity may play an important role in PD pathogenesis (6).

Increasing evidence suggests that *Drosophila melanogaster* is an excellent model organism for studying neuronal degenerative

diseases (16, 17) such as PD, Alzheimer's disease, tauopathies, amyotrophic lateral sclerosis, hereditary spastic paraplegia and polyglutamine diseases, and spinocerebellar ataxia (17, 18). The *LRRK2* gene is highly conserved across species. *Drosophila* has a single orthologue of the human *LRRK2* (*CG5483*), and a loss of function in this gene has been described (19). However, the loss-of-function mutation of *Drosophila CG5483* does not constitute an adequate model for the most common forms of *LRRK2*-linked PD, which appear to be gain-of-function mutations (like G2019S). To create a pathogenic gain-of-function model for *LRRK2*-linked disease, we generated transgenic flies expressing full-length human wild-type *LRRK2* and mutant *LRRK2*-G2019S. We found that overexpression of *LRRK2* or *LRRK2*-G2019S led to retinal degeneration, selective loss of dopaminergic (DA) neurons, decreased climbing activity, and early mortality. Expression of mutant *LRRK2*-G2019S caused a more severe phenotype than wild-type *LRRK2*. Thus, the *LRRK2* transgenic flies recapitulated several key features of human parkinsonism, indicating that overexpression of *LRRK2* in flies may provide a model for the human disease.

## Results

**LRRK2 Induces Retinal Degeneration.** To address whether overexpression of wild-type human *LRRK2* and the mutant *LRRK2*-G2019S phenocopy the human disease in flies, we introduced these proteins in specific subsets of cells using the *GAL4/UAS* system (20). This system takes advantage of the yeast *GAL4* transcription factor, which binds specifically to the *upstream activation sequence* (*UAS*). Thus, *UAS*-linked transgenes can be expressed in specific cell types under the control of a given promoter (*promoter-GAL4*). To determine whether introduction of *LRRK2* and *LRRK2*-G2019S causes a parkinsonism-like phenotype, we first assayed for retinal degeneration, because photoreceptor cell death has been used to assay neurodegeneration in other fly models of PD (18, 21). Therefore, we expressed two lines of *UAS-LRRK2* (1 and 4) and two lines of *UAS-LRRK2-G2019S* (2 and 3) in photoreceptor cells, under the control of the *glass multiple reporter* (*GMR-GAL4*). Using antibodies directed against the N-terminal Flag tags, we found that the wild-type and mutant proteins were stably expressed (Fig. 1A).

The fly compound eye comprises ≈800 repeat units, ommatidia, each including seven photoreceptor cells in any given plane of section. Each photoreceptor cell has a microvillar structure, the rhabdomere, which is the site of photoreception and is the invertebrate equivalent of the rod and cone outer segment. To examine the kinetics of retinal degeneration, we used the optical neutralization technique. As shown, retinal degeneration was

Author contributions: W.W.S. designed research; Z.L., X.W., Y.Y., X.L., T.W., H.J., Q.R., Y.J., and T.M. performed research; C.A.R. contributed new reagents/analytic tools; Z.L., A.S., C.M., and W.W.S. analyzed data; and C.M. and W.W.S. wrote the paper.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

¶To whom correspondence should be addressed at: Division of Neurobiology, Department of Psychiatry, Johns Hopkins University School of Medicine, CMSC 8-121, 600 North Wolfe Street, Baltimore, MD 21287. E-mail: wsmith60@jhmi.edu.

© 2008 by The National Academy of Sciences of the USA






**Fig. 3.** Expression of LRRK2 protein by *ddc-GAL4* driver induced loss of TH-positive DA neurons. (A) Diagram of DA and 5-HT neuron clusters in the medial and lateral areas of the adult fly brain as in previous publications (35, 36). (Left) Five clusters: PPM1 (unpaired), PPM2 (paired), PPM3 (paired; protocerebral posterior medial), and PPL1 and PPL2 (paired; protocerebral posterolateral) on the posterior side. (Center) Two DA clusters: PAL (protocerebral anterolateral) and PAM (paired anterolateral medial) on the anterior side. (Right) Five distinct 5-HT neuronal clusters (SP1, SP2, LP1, LP2, and IP) in the two brain hemispheres. (B–D) Dissected whole brains were subjected to anti-TH immunofluorescent staining. (B) Quantitation of TH-positive neurons in PPM1/2 clusters in transgenic flies of the indicated ages. (C) Average numbers of TH-positive neurons per DA cluster in 5-week-old flies of the indicated genotypes. (D) Representative images of anti-TH staining in PPM1 and PPM2 clusters from 5-week-old flies of the indicated genotypes. Statistically significant differences between the control and all *LRRK2* transgenic lines are indicated: \*,  $P < 0.05$  by ANOVA. Statistically significant differences between *LRRK2-1* and *G2019S-2* flies are indicated: #,  $P < 0.05$  by ANOVA.

rons of all DA neuron clusters and colocalized with anti-TH immunostaining (data not shown). To assess whether expression of LRRK2 resulted in degeneration of DA neurons, brains from transgenic flies at 1, 21, 35, and 49 days after eclosion were dissected and immunostained with anti-TH antibodies. In control flies (*ddc-GAL4* or *UAS-LRRK2* flies), the DA clusters did not change significantly in number or morphology during aging, as monitored by anti-TH staining (Fig. 3B). At 1 day after eclosion, there were no differences in anti-TH-positive staining between the control and *LRRK2* or *LRRK2-G2019S* flies (Fig. 3B). However, at 5 weeks of age, anti-TH staining decreased significantly in flies expressing either wild-type or mutant *LRRK2-G2019S* (Fig. 3B–D). We counted the TH-positive cells in all clusters except in the paired anterolateral medial (PAM) cluster, because the density of the neurons in PAM was too high to allow precise quantification. We found statistically significant TH-positive neuronal loss in all of the DA clusters examined (Fig. 3C). In addition, mutant *LRRK2-G2019S* caused more TH-positive neuronal loss than wild-type *LRRK2* at equivalent expression levels (Fig. 3B–D). Although L-DOPA improved the mutant *LRRK2*-induced locomotor impairment, it did not prevent the loss of TH-positive neurons (data not shown).


Because *ddc-GAL4* can also lead to *LRRK2* transgenes expressing in serotonin (5-HT) neurons, we also examined whether *LRRK2* protein affected 5-HT neurons using anti-5-HT whole-



**Fig. 4.** Expression of LRRK2 by *elav-GAL4* driver caused late-onset locomotor impairment. (A and B) Expression of *CG5483* and human *LRRK2* in various types of fly brain tissues. Total RNA was prepared from fly brain tissues, and cDNA was generated. Semiquantitative RT-PCR was performed by using primers for *CG5483* and human *LRRK2* to assess mRNA levels. (A) Representative image of RT-PCR products. (B) Quantitative analysis of relative mRNA levels of *CG5483* and human *LRRK2*. \*,  $P < 0.05$  versus *UAS-LRRK2* by ANOVA. (C) LRRK2 autophosphorylation (kinase) analysis of various fly head homogenates. Anti-Flag-LRRK2 immunoprecipitated samples from fly head homogenates were incubated with [ $\gamma$ - $^{32}$ P]ATP, subjected to SDS/PAGE, and blotted onto PVDF membranes. The samples were then imaged by using a phosphorimaging system. The incorporation of [ $\gamma$ - $^{32}$ P]ATP into LRRK2 protein increased by  $\approx 2.8$ -fold in *elav-GAL4;G2019S-2* flies compared with *elav-GAL4;LRRK2-1* flies. Shown are representative images from three independent experiments. (D) Cohorts of 60 flies from each genotype were subjected to climbing assays weekly. Statistically significant differences between the control and all *LRRK2* transgenic lines are indicated: \*,  $P < 0.05$  by ANOVA. Statistically significant differences between *LRRK2-1* and *G2019S-2* flies are indicated: #,  $P < 0.05$  by ANOVA. (E) Survival curves of flies expressing either *LRRK2* or *LRRK2-G2019S* ( $n = 50$ ).

mount brain immunohistochemical analysis. We found that the brains of flies expressing either wild-type or mutant *LRRK2-G2019S* at 5 and 7 weeks after eclosion displayed 5-HT immunoreactivity (data not shown) similar to that of the control flies.

**Expression of LRRK2 in All Neurons Causes Late-Onset Locomotion Impairment and Selective Loss of TH-Positive Neurons.** To further determine the effect of LRRK2, we expressed LRRK2 protein using the panneuronal driver, the embryonic lethal abnormal visual system gene (*elav*)-*GAL4*, achieving comparable levels of expression in *elav-GAL4;LRRK-1* and *elav-GAL4;G2019S-2* fly brains by RT-PCR (Fig. 4A and B) and anti-Flag Western blot (Fig. 4C). The human *LRRK2* transgene transcripts were more abundant than *CG5483* (Fig. 4A and B). Importantly, we found that the protein kinase activity in homogenates from *elav-GAL4;G2019S-2* fly heads was  $\approx 2.8$ -fold higher than that measured in *elav-GAL4;LRRK2-1* (Fig. 4C). At 1 week after eclosion, flies expressing either wild-type or mutant *LRRK2* under the control of *elav-GAL4* displayed normal locomotor activity (Fig. 4D). However, by 6 weeks, the climbing assay showed significant motor impairment in *elav-GAL4;G2019S-2* flies and a slight



**Fig. 5.** Expression of LRRK2 in all neurons caused selective loss of anti-TH-positive neurons. (A) Anti-elav whole-mount brain immunofluorescence of flies at 5 weeks after eclosion showed that expression of either LRRK2-1 or G2019S-2 did not significantly change the density of immunofluorescence. There was a slight but not significant decrease in anti-elav staining in LRRK2 transgenic flies. This could be due to loss of anti-TH-positive neurons. (B) Anti-5-HT whole-mount brain immunofluorescence of flies at 5 week after eclosion showed that expression of either LRRK2-1 or G2019S-2 did not cause loss of 5-HT-positive neurons. (C) Anti-TH whole-mount brain immunofluorescence of flies at 5 weeks after eclosion showed that expression of G2019S induced loss of TH-positive neurons. (D) Representative images of whole-mount brain sections of flies 5 weeks after eclosion. (Left) Anti-elav staining brain section. (Center) SP1, SP2, and IP 5-HT neuronal clusters with anti-5-HT staining. (Right) PPM1 and PPM2 TH-stained DA neuronal clusters.

deficit in *elav-GAL4;LRRK2-1* flies compared with control flies (Fig. 4D). The climbing performance of flies expressing either LRRK2-1 or LRRK2-G2019S-2 declined more rapidly than that of control flies. Moreover, the mutant *LRRK2-G2019S* flies exhibited more severe impairment than did the wild-type flies 6 week after eclosion (Fig. 4D). We also found that expression of LRRK2-1 and LRRK2-G2019S-2 shortened the lifespan compared with control flies (Fig. 4E). The ages at which 50% of the *LRRK2-1* and *G2019S-2* transgenic flies survived were 49 and 55 days, respectively.

Analysis of brains of *elav-GAL4;G2019S-2* flies at 5 weeks of age revealed reductions in TH immunoreactivity up to 22% in DA clusters whereas the *elav-GAL4;LRRK2-1* flies showed only a slight decrease (Fig. 5 C and D). At 7 weeks of age, flies expressing LRRK2-1 or LRRK2-G2019S-2 showed significant decreases in anti-TH staining up to 28% and 50%, respectively. In contrast, there were no significant changes in anti-elav and anti-5-HT immunostaining at 5 weeks (Fig. 5) and 7 weeks (data not shown) of age compared with nontransgenic control flies. These results indicate that expression of LRRK2 proteins was selectively toxic for DA neurons and that LRRK2-G2019S was more toxic than wild-type LRRK2.

## Discussion

Mutations in the *LRRK2* gene represent the most common known cause of PD (1, 2, 24). Unlike mutations in other PD-linked genes, *LRRK2*-linked disease has a clinical progression and neurochemical phenotype similar to that of typical late-onset disease, but little is known about LRRK2-linked molecular pathogenesis. Here we have created gain-of-function LRRK2 *Drosophila* models by overexpressing the human wild-type LRRK2 and the mutant form LRRK2-G2019S. Expression

of both forms of LRRK2 led to retinal degeneration, selective loss of DA neurons in the brain, early mortality, and locomotor impairment. Moreover, LRRK2-G2019S caused a more severe parkinsonism-like phenotype than wild-type LRRK2. Treatment with L-DOPA improved the mutant LRRK2-induced locomotor impairment but did not prevent the loss of TH-positive neurons, similar to LRRK2-linked human PD.

Expression of LRRK2 in all neurons under the control of the *elav-GAL4* caused a less severe phenotype in flies than specific expression of LRRK2 in DA neurons under the control of the *ddc-GAL4*, although the expression levels of proteins in fly head homogenates was higher in *elav-GAL4;LRRK2* flies. This paradox may be explained by the lower expression of LRRK2 proteins in DA neurons by *elav-GAL4*. LRRK2 triggered the loss of anti-TH immunostaining but not the significant loss of anti-elav or anti-5-HT immunostaining, indicating that LRRK2-induced toxicity is preferentially localized to DA neurons in the brain, which is reminiscent of human PD. The manifestation of symptoms in PD patients is associated with the loss of 50–60% of DA neurons (25–27). We found that 5-week-old *ddc-GAL4;G2019S-2* flies and 7-week-old *elav-GAL4;G2019S-2* flies had an  $\approx 50\%$  reduction of TH-positive neurons. These results indicated that LRRK2 induced the loss of DA neurons or TH expression. In either case there would be loss of DA function. Moreover, the *LRRK2* flies displayed parallel kinetics in the loss of TH-positive neurons and locomotor dysfunction, suggesting that these abnormalities may be causally related.

Expression of wild-type LRRK2 protein was toxic, albeit less so than expression of LRRK2-G2019S. These results raise the possibility that an elevated concentration of wild-type LRRK2 protein under some circumstances, such as genetic variation or cellular stress, may lead to DA neuronal degeneration and locomotor impairment and subsequently may contribute to some cases of human PD. As a related example, genetic duplication or triplication at the  $\alpha$ -synuclein locus leading to overexpression of wild-type  $\alpha$ -synuclein caused PD (28), although there are as yet no similar reports that elevated expression of wild-type LRRK2 links to human PD. A recent report shows that the disease phenotype and mortality of patients with heterozygous versus homozygous G2019S mutations are similar (29). However, there was an expression-level-dependent effect in phenotype between different G2019S fly lines. G2019S-2, which had a higher expression level than G2019S-3, has a faster rate of mortality and locomotor impairment than G2019S-3. At comparable expression levels, the mutant G2019S-LRRK2 had a more severe phenotype than wild-type LRRK2. The G2019S-3 line had much lower expression than wild-type LRRK2-1 but had a faster rate of mortality. We further found that mutant G2019S-2 had higher autophosphorylation activity than wild-type LRRK2-1. These results are consistent with *in vitro* findings that mutant LRRK2-G2019S has higher protein kinase activity and causes greater toxicity than wild-type LRRK2 (5, 10–14). A recent report shows that the G2019S mutation in LRRK2 appears to increase autophosphorylation through a process that seems to involve reorganization of the kinase activation segment and suggests a molecular explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity (13). Another possibility is that LRRK2 may act as a scaffold protein to alter other signaling molecules leading to pathogenicity through its specific protein–protein interaction domains (LRR and WD40). Clarifying the effects of PD-associated mutation on kinase activity and PD pathogenesis awaits the identification of true LRRK2 substrates and interaction partners. LRRK2 *Drosophila* may be a potential useful *in vivo* system to identify these LRRK2 interactors or substrates.

*Drosophila CG5483* (the fly homolog of LRRK2) is expressed in all tissues examined and may be enriched in brain and thoracoabdominal ganglion according to the FlyBase database

(<http://flybase.bio.indiana.edu/reports/FBgn0038816.html>) by cDNA array. The loss-of-function mutant studies indicate that the *Drosophila CG5483* protein is critical for the integrity of fly DA neurons (16). Transgenic expression of *Drosophila* wild-type *CG5483* and a mutation (R1069C) corresponding to the human R1441C mutation does not show any significant defects (16). This mutation in the context of *Drosophila CG5483* may not be as pathogenic as the same R1441C change in the context of the human LRRK2 patients. Alternatively, the expression level of this mutant allele may not reach the pathology threshold in the fly. A recent report shows that overexpression of mouse LRRK2 with a mutation corresponding to the R1441C mutation in human LRRK2 results in biochemical features similar to those of human LRRK2-R1441C; whether these mice display motor dysfunction and DA neuronal loss has not been reported (30). Introduction of the human LRRK2 protein kinase domain fragment into adult rat substantia nigra, via adenoassociated virus-2-mediated gene transduction, has been reported to cause of degeneration of DA neurons (5).

To our knowledge, our study is the first report of an animal gain-of-function model expressing full-length human LRRK2. The limitations of our study are that we have used only one mutation (albeit the most common) and that LRRK2 proteins may be overexpressed relative to the endogenous fly LRRK2 homolog. However, flies with lower expression had a phenotype similar to those with higher expression, just less severe. The findings in this study need to be extended to vertebrate animals and compared with human patients. It is noteworthy that the phenotype of the LRRK2 flies recapitulates several key features of the human disorder and can be improved by L-DOPA, thereby representing a valuable genetic model for pathogenesis study of LRRK2-linked parkinsonism. This model may be useful to screen for LRRK2 interactors and to search for LRRK2 substrates. No effective treatments are as yet available to prevent the progressive death of DA neurons in PD. The *Drosophila* model of mutant  $\alpha$ -synuclein has unveiled a gain-of-function mechanism for mutant  $\alpha$ -synuclein-linked PD and provided a model for testing neuroprotective strategies for  $\alpha$ -synuclein-mediated toxicity (18, 31). Similarly, the LRRK2 flies may provide a useful *in vivo* model for therapeutic screens to prevent neuronal loss and to rescue locomotor dysfunction in PD.

## Methods

**Generation of Human LRRK2 Transgenic Flies.** To generate *UAS-LRRK2* and *UAS-LRRK2-G2019S* transgenic flies, the genes encoding these human proteins with N-terminal Flag tags were excised from pcDNA3.1 vectors, cloned between the XhoI site of pUAST vector (20), and verified by sequencing. The resulting constructs were microinjected in *w<sup>1118</sup>* fly embryos (Rainbow Transgenic Flies). We obtained two transgenic lines each of *UAS-LRRK2* and *UAS-LRRK2-G2019S*. The LRRK2 expression levels were examined by anti-Flag Western blot analysis. We used *elav-GAL4*, *ddc-GAL4* (32), and *GMR-GAL4* (33) to express *UAS-LRRK2* and *UAS-LRRK2-G2019S* in all neurons, DA neurons, and photoreceptor cells, respectively. We selected two representative wild-type (*LRRK2-1* and *LRRK2-4*) and mutant (*G2019S-2* and *G2019S-3*) lines to conduct the phenotype characterization. *Drosophila* were grown on standard cornmeal medium at 25°C.

**Western Blot Analysis.** Adult fly heads were homogenized at 4°C in buffer A (50 mM Tris-HCl, pH 7.5/1 mM EGTA/0.5 M NaCl/1% Triton X-100/1 mM DTT with protease inhibitors) and extracted as described (33). The resulting homogenates were subjected to Bradford protein assays to ensure equal protein loading and resolved on 4–12% SDS/NuPAGE Bis-Tris gels and transferred onto PVDF membranes (Invitrogen). The membranes were blocked in TBST (pH 7.4, 10 mM Tris-HCl/150 mM NaCl/0.1% Tween 20) containing 5% nonfat milk and then probed with anti-Flag antibody (Sigma). Proteins were detected by using enhanced chemiluminescence reagents (NEN).

**Optical Neutralization Technique.** Adult fly heads were mounted on microscope slides using clear nail varnish and observed under a light microscope

(33). To obtain a semiquantitative and unbiased index of retinal degeneration, the investigator counting the number of visible rhabdomeres did not know the genotype of the samples. The mean number of rhabdomeres per ommatidium was calculated. Rhabdomeres were counted by using cohorts of six flies of each genotype weekly during the lifespan of flies.

**Electron Microscopy.** Fly heads were hemisected under a dim red photographic safety light, fixed (2% paraformaldehyde/2% glutaraldehyde in 0.1 M sodium cacodylate/3 mM calcium chloride, pH 7.2) at 4°C overnight, and postfixed in reduced osmium tetroxide for 1 h. Samples were stained *en bloc* with 2% uranyl acetate (filtered) and dehydrated through a graded series of ethanol. Eyes were oriented in gelatin capsules (size 00) and cured at 50°C for 24 h. Blocks were sectioned on a Riechert Ultracut E with a low-compression Diatome Diamond knife. Eighty-nanometer sections were picked up on copper slot grids and stained with uranyl acetate followed by lead citrate. Grids were viewed on a Hitachi 7600 TEM operating at 80 kV, and digital images were captured with an AMT 1 K × 1 K CCD camera as described (33).

**Survival Curve.** Cohorts of 50 flies from each genotype were monitored for survival. Flies were maintained on standard media, and fresh food media were changed every 3–4 days. Mortality was scored daily and analyzed by using Kaplan–Meier survival curves. This experiment was repeated once.

**Climbing Assay.** We determined locomotor ability using a climbing assay (negative geotaxis assay) as described previously (23). Cohorts of 60 flies from each genotype were subjected to the assay weekly from 1 week to the time of death. The tested flies were age-matched, randomly selected, anesthetized, and placed in a vertical plastic column (length, 25 cm; diameter, 1.5 cm). After a 30-min recovery from CO<sub>2</sub> exposure, flies were gently tapped to the bottom of the column. We counted and calculated the percentage of flies that could climb to or above the median line of the cylinder in 10 seconds. Each week, the assay was repeated three times.

**Actometer Test.** Cohorts of 20 flies from each genotype were subjected to the actometer assay at 5 weeks of age. A single fly was placed in a small tube with food at one end and was monitored for 3 days under standard conditions of 12-h light and 12-h darkness intervals. Activity was recorded on the computer every time the fly crossed an infrared beam (locomotion actograms), and the data were grouped into 30-min bins as described (34).

**Real-Time RT-PCR.** To determine the expression of *CG5483* and human LRRK2 at the mRNA level, primers were designed targeting *CG5483* (5'-CGGCCTATTAAACGCCACAGCAA-3' and 5'-AACTGAAGTGTTCGCGAAGAACC-3') and human LRRK2 (5'-ATTGCGAACCTGGATGTCTCTCGT-3' and 5'-TCAGGCACGAAGCTCAGCTGATTA-3'), respectively. The semiquantitative real-time RT-PCR was performed by using Stratagene Mx3000P PCR motion and Brilliant II QRT-PCR Master Mix kit according to the manufacturer's protocol.

**Immunoprecipitation (IP) and *In Vitro* Autophosphorylation (Kinase) Assays.** IP experiments from fly head homogenates were performed with anti-FLAG-agarose (Sigma). Precipitates were washed twice with lysis buffer and twice with kinase assay buffer (Cell Signaling Technology). A kinase activity assay was described previously using autophosphorylation because the authentic substrate(s) is not yet known (12). Briefly, kinase reactions were carried out for 90 min at 30°C in 40  $\mu$ l of kinase assay buffer with the addition of 15  $\mu$ l of solution containing 50 mM MgCl<sub>2</sub>, 500  $\mu$ M ATP, and 10  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P]ATP (3,000 Ci/mmol). Reactions were stopped by the addition of Laemmli sample buffer and boiling for 5 min. Samples were separated on 4–12% SDS/PAGE and blotted onto PVDF membranes. Quantification was performed with a phosphorimager (Bio-Rad Molecular Imager FX).

**Immunostaining and Cell Counting.** Fluorescent immunostaining was performed on whole-mount dissected adult brain (23, 35) at 1, 21, 35, and 49 weeks of age. Cohorts of six to eight flies per genotype were used at each time point for immunostaining. The dissected brains were mounted in Vectashield (Vector Laboratories).

Rabbit polyclonal anti-TH (Chemicon), mouse monoclonal anti-TH (Immunostar), anti-5-HT (Sigma), anti-elav (Developmental Studies Hybridoma Bank), and anti-Flag-antibodies were used as the primary antibodies. Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 568 goat anti-mouse IgG (Invitrogen) were used as secondary antibodies. The numbers of DA and 5-HT neurons were scored in whole-mount brains under fluorescent (Zeiss LSM 250)

and/or confocal microscopy (Zeiss LSM 510). For quantification of loss of anti-elav staining in brain, entire brain sections were digitized with an image analysis system. NIH Image J software was used to measure the optical density of anti-elav staining within the entire brain section (six brain sections per experimental group).

**Data Analysis.** Quantitative data were expressed as arithmetic means  $\pm$  SEM based on at least three separate experiments. Statistically significant differ-

ences between two groups were analyzed by ANOVA. A *P* value  $<0.05$  was considered significant.

**ACKNOWLEDGMENTS.** This research was funded by the National Institute of Neurological Disorders and Stroke, the National Institutes of Health, the National Parkinson's Foundation, and the American Parkinson's Disease Association (W.W.S.) and by National Eye Institute Grant EY08117 (to C.M.).

1. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, et al. (2004) *Neuron* 44:595–600.
2. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. (2004) *Neuron* 44:601–607.
3. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, et al. (2006) *Ann Neurol* 59:388–393.
4. Rajput A, Dickson DW, Robinson CA, Ross OA, Dachselt JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ (2006) *Neurology* 67:1506–1508.
5. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A (2006) *Neuron* 52:587–593.
6. Cookson MR, Dauer W, Dawson T, Fon EA, Guo M, Shen J (2007) *J Neurosci* 27:11865–11868.
7. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, et al. (2005) *Lancet* 365:410–412.
8. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, et al. (2005) *Lancet* 365:412–415.
9. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, et al. (2005) *Lancet* 365:415–416.
10. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM (2005) *Proc Natl Acad Sci USA* 102:16842–16847.
11. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, et al. (2006) *Neurobiol Dis* 23:329–341.
12. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA (2006) *Nat Neurosci* 9:1231–1233.
13. Luzon-Toro B, de la Torre ER, Delgado A, Perez-Tur J, Hilfiker S (2007) *Hum Mol Genet* 16:2031–2039.
14. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR (2007) *Biochem J* 405:307–317.
15. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M (2006) *Hum Mol Genet* 15:223–232.
16. Cauchi RJ, van den Heuvel M (2006) *Neurodegener Dis* 3:338–356.
17. Marsh JL, Thompson LM (2006) *Neuron* 52:169–178.
18. Feany MB, Bender WW (2000) *Nature* 404:394–398.
19. Lee SB, Kim W, Lee S, Chung J (2007) *Biochem Biophys Res Commun* 358:534–539.
20. Brand AH, Perrimon N (1993) *Development* 118:401–415.
21. Haass C, Kahle PJ (2000) *Nature* 404:341–343.
22. Budnik V, White K (1988) *J Comp Neurol* 268:400–413.
23. Friggi-Grelin F, Coulom H, Meller M, Gomez D, Hirsh J, Birman S (2003) *J Neurobiol* 54:618–627.
24. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A (2006) *Ann Neurol* 60:389–398.
25. Dauer W, Przedborski S (2003) *Neuron* 39:889–909.
26. Forno LS (1996) *J Neuropathol Exp Neurol* 55:259–272.
27. Mouradian MM (2002) *Neurology* 58:179–185.
28. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. (2003) *Science* 302:841.
29. Ishihara L, Warren L, Gibson R, Amouri R, Lesage S, Durr A, Tazir M, Wszolek ZK, Uitti RJ, Nichols WC, et al. (2006) *Arch Neurol* 63:1250–1254.
30. Li X, Tan YC, Poulouse S, Olanow CW, Huang XY, Yue Z (2007) *J Neurochem* 103:238–247.
31. Auluck PK, Meulener MC, Bonini NM (2005) *J Biol Chem* 280:2873–2878.
32. Li H, Chaney S, Roberts IJ, Forte M, Hirsh J (2000) *Curr Biol* 10:211–214.
33. Xu H, Lee SJ, Suzuki E, Dugan KD, Stoddard A, Li HS, Chodosh LA, Montell C (2004) *EMBO J* 23:811–822.
34. Rothenfluh A, Abodeely M, Price JL, Young MW (2000) *Genetics* 156:665–675.
35. Chaudhuri A, Bowling K, Funderburk C, Lawal H, Inamdar A, Wang Z, O'Donnell JM (2007) *J Neurosci* 27:2457–2467.
36. Monastirioti M (1999) *Microsc Res Tech* 45:106–121.